Here below are the publications (1) participated by Ursula Maria Vogl along with Andrea Alimonti (as cross-checked throughout PubMed, counted from 2020, including only Ticino affiliations).
Any wrong or incomplete data? Any missing, misplaced, unlicensed picture? Please report any abuse, inaccuracy or lack of information to info@ticinoscienza.ch
Ursula Maria Voglis currently collaborating with
Istituto Oncologico Svizzera Italiana (IOSI) (Rif. IOSI)
Via Gallino 12 (ex Via Ospedale)
6500 Bellinzona
Ursula Maria Vogl
on behalf of
Istituto Oncologico Svizzera Italiana (IOSI) EOC (Rif. IOSI)
is currently Research Program Leader [Rif. 50110] for
on physical activity and diet in patients with metastatic prostate cancer receiving novel hormonal agents: the ACTIDIET-PRO study (Rif. 34000 202407)
on behalf of
Istituto Oncologico Svizzera Italiana (IOSI) EOC (Rif. IOSI)
is currently Research Program Leader [Rif. 50110] for
on physical activity and diet in patients with metastatic prostate cancer receiving novel hormonal agents: the ACTIDIET-PRO study (Rif. 34000 202407)
Ursula Maria Vogl
on behalf of
Istituto Oncologico Svizzera Italiana (IOSI) EOC (Rif. IOSI)
is currently Research Program Leader [Rif. 50110] for
A Phase 1 Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 509 in Subjects With Metastatic Castration-Resistant Prostate Cancer (Rif. 13000 202407)
on behalf of
Istituto Oncologico Svizzera Italiana (IOSI) EOC (Rif. IOSI)
is currently Research Program Leader [Rif. 50110] for
A Phase 1 Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 509 in Subjects With Metastatic Castration-Resistant Prostate Cancer (Rif. 13000 202407)
Ursula Maria Vogl
on behalf of
Istituto Oncologico Svizzera Italiana (IOSI) EOC (Rif. IOSI)
is currently Research Program Leader [Rif. 50110] for
Protocol SAKK 06/19 Intravesical BCG followed by perioperative chemo-immunotherapy for patients with muscle-invasive bladder cancer (MIBC). A multicenter, single-arm phase II trial (Rif. 37000 202407)
on behalf of
Istituto Oncologico Svizzera Italiana (IOSI) EOC (Rif. IOSI)
is currently Research Program Leader [Rif. 50110] for
Protocol SAKK 06/19 Intravesical BCG followed by perioperative chemo-immunotherapy for patients with muscle-invasive bladder cancer (MIBC). A multicenter, single-arm phase II trial (Rif. 37000 202407)